A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106
This study is recruiting at 4 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Amyloid Plaque
- Beta-Amyloid
- DSAD
- Prodromal Alzheimer's Disease
- Alzheimer's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 35 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AC Immune SA
- Last updated on ClinicalTrials.gov
- July 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 3
- K2 Medical Research The Villages LLC · Lady Lake, FL
- Charter Research, LLC · Orlando, FL
- Charter Research, LLC · The Villages, FL
Tennessee · 1
- Neurology Clinical, P.C. · Cordova, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.